according to the FTC. They also allegedly used the allure of rebates to lure new clients. The agency contends that even when lower drug priced insulin was available, the PBMs "systemically ...
The FTC accused the companies of creating a “perverse” drug rebate system that prioritizes insulin from manufacturers sold at a higher list price even when cheaper versions are available.
Some results have been hidden because they may be inaccessible to you
Feedback